Uterine fibroids (leiomyomas) constitute a major global public health concern, with an estimated prevalence of up to 70-80% of women experiencing them by age 50. While many are asymptomatic, the symptomatic population—approximately 30%—experiences significant morbidity, including heavy menstrual bleeding (leading to anemia), chronic pelvic pain, and infertility.

The market drivers are inherently linked to demographics: the risk is highest in women of reproductive age (peaking in the 40s) and is disproportionately higher in certain racial groups, notably Black women. Beyond the clinical impact, the condition imposes a colossal socioeconomic burden. In high-income nations like the United States, the total annual costs (direct healthcare expenses from surgeries and procedures, plus indirect costs from lost productivity and disability) are estimated to be in the tens of billions of dollars. This rising burden across populations underscores the pressing need for effective, long-term management solutions in the Uterine Fibroid Market, as detailed in disease incidence analyses, such as the Uterine Fibroid Market Global Outlook.